Sudeep Pharma, a global manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients, delivered an impressive listing on the stock exchanges today, opening at ₹733.95 on the BSE, logging a 23.76% premium over its IPO price of ₹593 per share. On the NSE, the pharma stock debuted at ₹730, up 23.1% against the issue price.

Post listing, the stock gained as much as 34% to hit a high of ₹793.35 on the BSE, in an otherwise muted broader market.

At the time of reporting, Sudeep Pharma shares were trading at ₹783.35, up 32.1% over the IPO price, while its market capitalisation stood at ₹8,844.44 crore. Meanwhile, the BSE Sensex and NSE Nifty were trading higher by 0.15% each.

The debut of Sudeep Pharma’s IPO was better than Street expectations, as the stock was commanding a grey market premium of ₹121 in the unlisted market, indicating a listing price of around ₹714, up 20.40%.

“The strong debut reflects robust investor confidence in the company’s position as a leading player in specialty pharma ingredients and excipients,” said Shivani Nyati, Head of Wealth at Swastika Investmart.

She added that enthusiasm around the IPO was evident well before listing day, thanks to the overwhelming response to the issue and a strong grey market premium.

“Sudeep Pharma’s listing strength is backed by its established presence in pharma and nutraceutical input materials, diversified product portfolio, long-term relationships with leading global pharma companies, and strong export potential. However, in the near term, investors may remain watchful of margin sustainability, raw material price swings, and competitive intensity in specialty chemicals and pharma ingredients.”

Nyati added that investors allocated shares may consider booking partial gains, while aggressive long-term investors bullish on the specialty pharma ingredients space may hold the remaining portion. She recommended a stop-loss at ₹690.

The ₹895 crore IPO of Sudeep Pharma, which was a combination of a fresh issue of shares aggregating to ₹95 crore and an offer for sale aggregating to ₹800 crore, was subscribed 93.72 times. The issue received bids for 99,00,86,575 shares against the 1,05,64,926 equity shares offered, at a price band of ₹563–593, according to data available on the stock exchanges.

The qualified institutional buyers’ portion and the non-institutional investors’ portion were subscribed 213.1 times and 116.7 times, respectively, whereas the retail portion was subscribed 15.65 times.

The issue opened for subscription on November 21, 2025, and closed on November 25, 2025.

Formed in 1989, Sudeep Pharma is a manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries, serving over 100 countries. The company has established a presence in both domestic and international markets, including key regions such as the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.

The firm’s revenue from operations during the June 2025 quarter was ₹124.9 crore, and its net profit was ₹28.4 crore. The revenue from operations stood at ₹502 crore during FY25, compared with ₹428.7 crore during FY23. Its net profit was ₹137 crore during FY25, compared with ₹60.4 crore during FY23.

(DISCLAIMER: The views and opinions expressed by investment experts on fortuneindia.com are either their own or of their organisations, but not necessarily that of fortuneindia.com and its editorial team. Readers are advised to consult certified experts before taking investment decisions.)